270 related articles for article (PubMed ID: 29367417)
1. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study.
Kang EH; Jin Y; Brill G; Lewey J; Patorno E; Desai RJ; Kim SC
J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29367417
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
[TBL] [Abstract][Full Text] [Related]
3. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
4. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.
Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
Semin Arthritis Rheum; 2018 Dec; 48(3):399-405. PubMed ID: 29673963
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
Zhang J; Xie F; Yun H; Chen L; Muntner P; Levitan EB; Safford MM; Kent ST; Osterman MT; Lewis JD; Saag K; Singh JA; Curtis JR
Ann Rheum Dis; 2016 Oct; 75(10):1813-8. PubMed ID: 26792814
[TBL] [Abstract][Full Text] [Related]
7. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
[TBL] [Abstract][Full Text] [Related]
8. Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents.
Desai RJ; Varma VR; Gerhard T; Segal J; Mahesri M; Chin K; Horton DB; Kim SC; Schneeweiss S; Thambisetty M
JAMA Netw Open; 2022 Apr; 5(4):e226567. PubMed ID: 35394510
[TBL] [Abstract][Full Text] [Related]
9. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
[TBL] [Abstract][Full Text] [Related]
10. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
[TBL] [Abstract][Full Text] [Related]
11. Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study.
Kang EH; Jin Y; Desai RJ; Liu J; Sparks JA; Kim SC
Semin Arthritis Rheum; 2020 Jun; 50(3):401-408. PubMed ID: 31813561
[TBL] [Abstract][Full Text] [Related]
12. Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.
Chen SK; Liao KP; Liu J; Kim SC
Arthritis Care Res (Hoboken); 2020 Jan; 72(1):9-17. PubMed ID: 30570833
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Xie F; Yun H; Bernatsky S; Curtis JR
Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.
Solomon DH; Curtis JR; Saag KG; Lii J; Chen L; Harrold LR; Herrinton LJ; Graham DJ; Kowal MK; Kuriya B; Liu L; Griffin MR; Lewis JD; Rassen JA
Am J Med; 2013 Aug; 126(8):730.e9-730.e17. PubMed ID: 23885678
[TBL] [Abstract][Full Text] [Related]
16. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.
Yun H; Xie F; Beyl RN; Chen L; Lewis JD; Saag KG; Curtis JR
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1526-1534. PubMed ID: 27813327
[TBL] [Abstract][Full Text] [Related]
17. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.
Montastruc F; Renoux C; Dell'Aniello S; Simon TA; Azoulay L; Hudson M; Suissa S
Rheumatology (Oxford); 2019 Apr; 58(4):683-691. PubMed ID: 30535094
[TBL] [Abstract][Full Text] [Related]
18. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive.
Harrold LR; Wittstock K; Kelly S; Han X; Zhuo J; Schrader A; Middaugh N; Moore PC; Khaychuk V
Adv Rheumatol; 2024 Jan; 64(1):10. PubMed ID: 38243281
[TBL] [Abstract][Full Text] [Related]
20. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D; Patil D; McDonald L; Patel V; Lobo F
J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
[No Abstract] [Full Text] [Related]
[Next] [New Search]
